Last updated on August 2018

COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention


Brief description of study

The primary purpose of this study is to determine whether treatment with the Cobra PzF stent with 14 day Dual Anti-Platelet Therapy (DAPT) has a better safety profile compared to standard FDA approved Drug Eluting Stent plus 6-Month Dual Anti-Platelet Therapy in patients undergoing coronary intervention who also require oral anticoagulation.

Clinical Study Identifier: TX209900

Contact Investigators or Research Sites near you

Start Over

Priscilla Chu, Clinical Research Coordinator

Northwell Health Clinical Trials Office
Lake Success, NY USA
  Connect »